- Raised Series A led by NGT HealthCare II, Jul 2023
- Raised Seed round led by NGT HealthCare II, Apr 2023
- Raised Pre-Seed round led by NGT3, Jul 2021
About
IntraGel Therapeutics is a research-driven company focused on pioneering advanced treatments for solid tumors using its SRGel platform, a gel-based drug delivery technology. This injectable polymeric platform solidifies once injected into the body, slowly releasing trapped drugs over weeks to the surrounding area. The SRGel platform is designed to deliver sustained efficacy with minimal frequency and can be combined with various anti-cancer medications, such as cisplatin (its flagship product, TumoCure), paclitaxel, and temozolamide. The company is targeting head and neck cancer as its initial indication, aiming to provide a treatment option for patients unfit for conventional chemotherapy. IntraGel Therapeutics operates from the NGT3 technology incubator in Nazareth, Israel. The company is currently raising $5 million to advance FDA IND enabling studies, establish a GMP facility, and progress towards Phase II clinical trials.
Funding history · 3 rounds · — total
Headcount over time
Q&A
- What is IntraGel Therapeutics' primary focus?
- IntraGel Therapeutics is a research-driven company focused on developing advanced treatments for solid tumors using its SRGel platform, a gel-based drug delivery technology.
- What is the SRGel platform?
- The SRGel platform is an injectable polymeric gel-based drug delivery technology that solidifies upon injection, slowly releasing trapped drugs over weeks to the surrounding area. It is designed for sustained efficacy with minimal frequency.
- What is IntraGel Therapeutics' flagship product and its target indication?
- IntraGel Therapeutics' flagship product is TumoCure, which combines the SRGel platform with cisplatin. The company is initially targeting head and neck cancer as its primary indication.
- What is the current employee count for IntraGel Therapeutics?
- IntraGel Therapeutics has 6 employees, falling within the 1-10 employee bucket.
- What was IntraGel Therapeutics' most recent funding round?
- IntraGel Therapeutics secured a Pre-Seed round in May 2023, raising $450,000. Key investors included Israel Innovation Authority and NGT HealthCare II.
- Where is IntraGel Therapeutics headquartered?
- IntraGel Therapeutics is headquartered in Nazareth, Israel, and operates from the NGT3 technology incubator.
- What are IntraGel Therapeutics' current fundraising goals?
- IntraGel Therapeutics is currently raising $5 million to advance FDA IND enabling studies, establish a GMP facility, and progress towards Phase II clinical trials.
- Who are the co-founders of IntraGel Therapeutics?
- The co-founders of IntraGel Therapeutics are Peter Siman (who also serves as CEO), Avner Geva, and Avi Domb.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | intra-gel.com |
|---|---|
| linkedin.com/company/72377575 | |
| facebook.com/IntraGel-Therapeutics-103823218528283 |
Identifiers & details
| Legal name | INTRAGEL THERAPEUTICS LTD |
|---|---|
| Founded | 2020-12 |
| Employees (exact) | 6 |
Radar intelligence
Patents
| EPO | 2 |
|---|
Web history (Wayback)
| Domain | intra-gel.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516293677 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2020-12-09 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 1 |
| Registry events | 1 — charge (1) |
| Registered address | ואדי אל-חאג' 13 נצרת |
Recent registry events
| Date | Event |
|---|---|
| 2026-01-15 | רישום שעבוד |